Study of ofirnoflast for people with low-risk myelodysplastic syndromes needing blood transfusions
Part of Blood & lymphatic clinical trials.
This trial tests a new oral medication, ofirnoflast, for people with a blood disorder called myelodysplastic syndromes (MDS) that is low risk but requires regular red blood cell transfusions. The goal is to see if the drug can improve blood counts and reduce transfusion needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have very low-, low-, or intermediate-risk MDS and are anemic.
- Your disease has not responded to or has come back after 1 to 3 prior treatments.
- You have not had certain other cancers or blood disorders.
- You can swallow tablets and are willing to have a bone marrow sample taken.
- You are not severely kidney or liver impaired, and do not have uncontrolled infections or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
This study tests a new therapy called MNV-201 for people with low-risk myelodysplastic syndromes (MDS) who have anemia and need regular blood transfusions. The goal is to see if this treatment can help reduce or stop the need for transfusions.
This trial tests whether a structured lifestyle program can help people with low-risk myelodysplastic syndromes (MDS) manage their health better. It mainly targets adults who are not getting frequent blood transfusions and have low hemoglobin levels.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This trial tests an experimental drug called AND017 for people with a certain type of myelodysplastic syndrome (MDS) that is low-risk and not linked to a chromosome 5 deletion. The goal is to see if AND017 can help improve low red blood cell counts (anemia) and reduce or avoid the need for blood transfusions.
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.